iShares U.S. Pharmaceuticals ETF (IHE) Price, Holdings, & News $178.33 +0.69 (+0.39%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$177.13▼$178.5050-Day Range$166.63▼$181.9752-Week Range$166.09▼$191.74Volume18,429 shsAverage Volume14,161 shsMarket Capitalization$365.57 millionAssets Under Management$588.21 millionDividend Yield2.09%Net Expense Ratio0.39% Stock AnalysisStock AnalysisChartHeadlinesHoldingsOwnershipRatingsStock AnalysisChartHeadlinesHoldingsOwnershipRatings About iShares U.S. Pharmaceuticals ETFiShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Due to the use of representative sampling, the Fund may or may not hold all of the securities that are included in the Index. The Fund’s investment advisor is BlackRock Fund Advisors.Read More IHE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IHE ETF News HeadlinesNovember 17, 2023 | seekingalpha.comIHE iShares U.S. Pharmaceuticals ETFNovember 15, 2023 | lse.co.ukIshares Uk Property Ucits Etf Gbp Dist Share Price (IUKP.MI)December 9, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 12, 2023 | lse.co.ukIshares $ Ultrashort Bond Ucits Etf Share Price (ERND.AM)October 19, 2023 | msn.comIs Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?October 18, 2023 | finance.yahoo.comJNJ Beats Q3 Earnings Estimates, Raises View: ETFs in FocusAugust 21, 2023 | msn.comIHE: A Highly Concentrated Portfolio Is Able To Generate Growth Over The Long RunAugust 15, 2023 | finance.yahoo.comThe Zacks Analyst Blog Highlights URNJ, IHE and PXEDecember 9, 2023 | Autonomix (Ad)How to Invest Early In the Next Potential Breakthrough Nerve-Sensing TechnologyAutonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comAugust 15, 2023 | msn.comPharma ETF (IHE) Hit a 52-Week HighSee More Headlines Receive IHE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iShares U.S. Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssueriShares Fund NameiShares U.S. Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:IHE Inception Date5/1/2006 Fund ManagerDiane Hsiung, Jennifer Hsui, Greg Savage, Alan Mason Webwww.iShares.com PhoneN/AFund Focus Asset ClassEquity BenchmarkDow Jones U.S. Select Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings38 Fund Statistics Assets Under Management$588.21 million Average Daily Volume$14,094.10 Discount/Premium0.08% Administrator, Advisor and Custodian AdministratorCitibank, N.A. AdvisorBlackRock Fund Advisors CustodianCitibank, N.A. DistributorBlackRock Investments, LLC Transfer AgentCitibank, N.A. TrusteeN/A Lead Market MakerLatour Trading Options OptionableN/A Short Interest33,700 shs Miscellaneous Outstanding Shares2,050,000Beta0.70 Creation Unit50,000 Creation Fee$306.00 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report iShares U.S. Pharmaceuticals ETF ExpensesTypeIHEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.39%0.56%0.53%0.50%0.51%Other Expenses0.00%0.40%0.54%0.64%0.57%Total Expense0.39%0.72%0.70%0.73%0.70%Fee Waiver0.00%-0.51%-0.54%-0.69%-0.57%Net Expense0.39%0.61%0.60%0.57%0.57% iShares U.S. Pharmaceuticals ETF (IHE) Holdings & ExposureTop 10 IHE HoldingsEli Lilly and Company(NYSE:LLY)Holding Weight: 24.95%Johnson & Johnson(NYSE:JNJ)Holding Weight: 22.68%Zoetis(NYSE:ZTS)Holding Weight: 4.83%Viatris(NASDAQ:VTRS)Holding Weight: 4.74%Merck & Co., Inc.(NYSE:MRK)Holding Weight: 4.06%Bristol-Myers Squibb(NYSE:BMY)Holding Weight: 3.93%Pfizer(NYSE:PFE)Holding Weight: 3.84%Royalty Pharma(NASDAQ:RPRX)Holding Weight: 3.78%Jazz Pharmaceuticals(NASDAQ:JAZZ)Holding Weight: 3.06%Catalent(NYSE:CTLT)Holding Weight: 2.95%IHE Sector ExposureIHE Industry ExposureFull Holdings Details Key ExecutivesGeorge G. C. Parker Ph.D. (Age 78)Independent Chairman of the Board of Trustees Michael Arthur Latham (Age 51)President, Trustee Jack Gee (Age 57)Chief Financial Officer, Treasurer Geoffrey D. FlynnChief Operating Officer, Executive Vice PresidentAmy Schioldager (Age 56)Executive Vice President Ira P. Shapiro (Age 52)Vice President, Chief Legal Officer Matt TuckerVice PresidentEilleen M. Clavere (Age 61)Secretary Cecilia H. Herbert (Age 68)Independent Trustee Charles A. Hurty (Age 73)Independent Trustee More ExecutivesSimilar ETFsVanEck Biotech ETFNASDAQ:BBHVanEck Pharmaceutical ETFNASDAQ:PPHSPDR S&P Health Care Equipment ETFNYSEARCA:XHEInvesco S&P 500 Equal Weight Health Care ETFNYSEARCA:RSPHiShares U.S. Healthcare Providers ETFNYSEARCA:IHFInstitutional OwnershipTrust Co. of VermontBought 603 shares on 11/27/2023Ownership: 0.029%Comerica BankBought 652 shares on 11/21/2023Ownership: 0.032%Creative PlanningSold 197 shares on 11/16/2023Ownership: 0.087%Ameriprise Financial Inc.Bought 844 shares on 11/15/2023Ownership: 0.121%GSA Capital Partners LLPBought 145 shares on 11/15/2023Ownership: 0.074%View All Institutional Transactions IHE ETF - Frequently Asked Questions How have IHE shares performed in 2023? iShares U.S. Pharmaceuticals ETF's stock was trading at $186.13 on January 1st, 2023. Since then, IHE stock has decreased by 4.2% and is now trading at $178.3259. View the best growth stocks for 2023 here. What does IHE invest in? iShares U.S. Pharmaceuticals ETF is a equity fund issued by iShares. IHE focuses on health care investments and follows the Dow Jones U.S. Select Pharmaceuticals Index. The fund's investments total to approximately $588.21 million assets under management. What stocks does iShares U.S. Pharmaceuticals ETF hold? IHE invests in 38 holdings. Some of the stocks in their portfolio include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Zoetis (ZTS), Viatris (VTRS), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Pfizer (PFE), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). What is the management fee for iShares U.S. Pharmaceuticals ETF? iShares U.S. Pharmaceuticals ETF's management fee is 0.39% and has no other recorded expenses or fee waivers. The net expense ratio for IHE is 0.39%. What other stocks do shareholders of iShares U.S. Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other iShares U.S. Pharmaceuticals ETF investors own include United Parcel Service (UPS), CVS Health (CVS), Genuine Parts (GPC), Intel (INTC), Kinder Morgan (KMI), Wells Fargo & Company (WFC), Archer-Daniels-Midland (ADM), BP (BP) and Campbell Soup (CPB). Who are iShares U.S. Pharmaceuticals ETF's major shareholders? iShares U.S. Pharmaceuticals ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include Envestnet Asset Management Inc. (3.12%), Raymond James & Associates (2.78%), Royal Bank of Canada (1.81%), RiverFront Investment Group LLC (1.76%), LPL Financial LLC (1.18%) and UBS Group AG (0.72%). How do I buy shares of iShares U.S. Pharmaceuticals ETF? Shares of IHE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NYSEARCA:IHE) was last updated on 12/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iShares U.S. Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.